Navigation Links
Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.

Mississauga, Ontario (PRWEB) May 21, 2013

Inflamax scientists worked closely with internationally renowned expert scientists of the ITN to design the study, which will provide critical insight into the usefulness of two key clinical models used in the study of allergy treatments, the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC) models. Although both the models are well recognized and supported by numerous publications, to date no direct comparison between the allergic responses evoked by them has been performed.

The study involves allergen challenge by the two methods, followed by collection of nasal secretions and blood work to identify the sequence of biomarkers and inflammatory cells involved in the early and late phase of the allergic reaction. Dr. Stephen Durham from the Imperial College London developed the NAC model, and he will be the study’s coordinating investigator. The protocol is being developed by Inflamax and the team at ITN.

“We are pleased that ITN and its group of internationally renowned scientists and clinicians, after reviewing the other available EEC facilities, chose to collaborate with Inflamax on this project. This highlights the unique and very high caliber of scientific expertise and experience that we provide. Collaborations and projects like this underline our core vision and mission to develop and provide the best, scientifically validated models to our clients.” Says Dr Piyush Patel, MD, CEO of Inflamax Research. “Inflamax provides the best of client focused CRO services with scientific expertise which is unparalleled even in the top academic institutions”.

“Sponsor organizations wishing to conduct clinical trials utilizing allergen challenge models including the EEC, need to ensure that the study is properly designed. So doing this kind of basic research reinforces the confidence in data validity, and increases the likelihood that regulators around the world accept the data. The scientific staff at Inflamax have designed and conducted many mechanistic, proof of concept and pivotal studies utilizing multiple allergen challenge models, and are the experts in both scientific design and EEC trial methodology.” says Dr. Anne Marie Salapatek, President and CSO of Inflamax.

Inflamax is developing in-house capability to measure biomarkers and has the expertise to recommend specific biomarkers to assay in order to understand the underlying mechanism of action. Typical markers for consideration may include IL1, IL5, Eosinophil Cationic Protein (ECP), tryptase and Th2 cytokines, specific immunoglobulin (IgG, IgG4, IgA, IgE, and FAB), basophil activation and HLA assays.

About Inflamax

Inflamax is a full service Contract Research Organization (CRO) specializing in Proof of Concept as well as Phase I through IV studies in allergy, asthma, ocular and dermatology utilizing EEC technology. Inflamax conducts single and multi-center Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax Research’s Mobile EECTM systems which can be positioned globally, Inflamax has 2 fixed EECs at Inflamax headquarters in Toronto, Canada. Inflamax’s EECs have been validated for study of allergy to ragweed, grass, cat and dust mite, as well as dry eye syndrome (utilizing low humidity EEC conditions).

About ITN

The Immune Tolerance Network (ITN) is an international clinical research consortium sponsored by NIAID, part of the National Institutes of Health.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
2. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
3. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. Vital Imaging Makes Greater Commitment into MRI Research
6. Phosphagenics Signs Research Agreement with the Agricultural Research Service
7. Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
8. Researchers identify signals that direct the immune system to reject a transplanted organ
9. NIH Saves Lives: Fred Hutchinson Cancer Research Center Calls On Congress To Restore Full NIH Funding
10. The Research Foundation for The State University of New York Enters Site License Agreement with 2Market Information Inc., Publisher of Technology Transfer Tactics
11. Contraceptives Market is Expected to Reach USD 23.3 Billion Globally in 2018: Transparency Market Research
Post Your Comments:
(Date:10/12/2015)... SAN FRANCISCO , October 12, 2015 ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ... detection market is expected to reach USD 6.49 billion ... Research, Inc. This growth in demand can be attributed to ...
(Date:10/12/2015)... CAESAREA, Israel , October 12, 2015 ... of the Dario™ Diabetes Management Solution, today announced its ... a patient case study at MobiHealth,s 5th EAI ... Focused on, "Transforming healthcare through innovations in mobile and ... London, England from October 14 - ...
(Date:10/12/2015)... ... ... NeuMedics Inc., is a specialty biopharmaceutical company focused on identifying and developing ... administered as an eye drop, announced today it has been selected to present at ... October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio. The purpose ...
(Date:10/10/2015)... , 10. Oktober, 2015 Am ... (Abgeordnete der Demokratischen Partei für Kalifornien) ihre Würdigung ... 17. Oktober) in die Aufzeichnungen des Kongresses eintragen ... Protein Therapeutics Association (PPTA) und ihren Mitgliedsunternehmen ... , Hebung des Bewusstseins über Plasmaspenden weltweit ...
Breaking Biology Technology:
(Date:9/28/2015)... , September 28, 2015 According ... (Hardware & Software), Product (Scanner & Others), Application (Access ... Defense, & Others) & Geography Global - Forecast to ... to reach USD 3627.90 Million by 2020, at a ... Browse 65 market data T ables and ...
(Date:9/24/2015)... , Sept. 24, 2015  EyeLock LLC, a market ... its award winning and latest technology in Booth #602 ... California . EyeLock,s iris authentication technology ... unmatched biometric accuracy, making it the most proven way ... uses video technology to deliver a fast and friendly ...
(Date:9/10/2015)... Report Details Emerging Biological ... and Revenue Prospects to Help You Stay Ahead ... new drug classes? Get the latest technological and ... market data and industry knowledge, benefitting your influence. ... and sales predictions. Visiongain,s new study reveals ...
Breaking Biology News(10 mins):